Key strengths include a strong liquidity position with net cash, conservative use of debt, and a large base of cash and short‑term investments that can support ongoing development. The company has demonstrated technical and regulatory success through an approved hemophilia B gene therapy and has built substantial manufacturing and platform capabilities in AAV gene therapy. High gross margins on existing revenue indicate good control over direct costs, while a deep, innovative pipeline across CNS and liver diseases offers multiple shots on goal for future value creation.

The main risks stem from persistent and substantial operating losses, heavy cash burn, and a long history of negative retained earnings, all of which mean the business is not self‑sustaining today. Success depends heavily on a relatively small number of key programs and on navigating complex, evolving regulatory pathways for gene therapies. Clinical trial setbacks, safety concerns, or delays could materially impact prospects. Over time, the company may need additional external funding, which could be challenging or dilutive if market conditions or trial results are unfavorable. Competitive and reimbursement pressures in high‑cost gene therapies add further uncertainty.

Looking ahead, uniQure’s prospects hinge on the balance between its scientific potential and its financial runway. In the near term, it is likely to remain loss‑making as it advances AMT‑130 and other programs, relying on its current cash resources and possible partnership inflows. If key clinical programs deliver strong data and the company secures clear regulatory paths and supportive commercial arrangements, its rich platform could translate into growing, higher‑quality revenue over time. Conversely, if pivotal trials disappoint or timelines extend significantly, the combination of ongoing cash burn and finite liquidity would become a more pressing concern. Overall, the story is one of high innovation and high risk, where execution on the pipeline will be critical.